An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)
暂无分享,去创建一个
C. Parker | J. Bono | C. Sternberg | M. Mason | J. Bellmunt | J. Droz | J. Graham | G. Zugmaier | M. Mason | K. Miller | K. Miller | V. Gimenez